Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Drug Delivery

• Publication date

  2015-08-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425247.2015.1069815PMID 26289676
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity.

  2015cited by this paper
• The neuroprotective effect of erythropoietin on experimental Parkinson model in rats.

  2015cited by this paper
• The Sleep-Modulating Peptide Orexin-B Protects Midbrain Dopamine Neurons from Degeneration, Alone or in Cooperation with Nicotine

  2015cited by this paper
• Network of hypothalamic neurons that control appetite

  2015cited by this paper
• Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats.

  2015influential reference
• Expression of GDNF Throughout Rat Brain After Intranasal Delivery of hGDNF Plasmid Nanoparticles

  2015cited by this paper
• Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice

  2015cited by this paper
• Acute and repeated intranasal oxytocin administration exerts anti-aggressive and pro-affiliative effects in male rats.

  2015cited by this paper
• Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain

  2014cited by this paper
• Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.

  2014cited by this paper
• IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice

  2014cited by this paper
• Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease

  2014cited by this paper
• Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model

  2014cited by this paper
• Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

  2014cited by this paper
• he effect of intranasal orexin-A ( hypocretin-1 ) on sleep , wakefulness nd attention in narcolepsy with cataplexy ara

  2014cited by this paper
• Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats.

  2014influential reference
• The neuroanatomical distribution of oxytocin receptor binding and mRNA in the male rhesus macaque (Macaca mulatta).

  2014cited by this paper
• Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease.

  2014cited by this paper
• Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease

  2014cited by this paper
• Biology of adeno-associated viral vectors in the central nervous system

  2014cited by this paper
• Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein

  2014cited by this paper
• Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.

  2014influential reference
• Intranasal nerve growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats.

  2014influential reference
• Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model.

  2014influential reference
• Intranasal oxytocin effects on social cognition: a critique.

  2014cited by this paper
• Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats.

  2014influential reference
• Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

  2013cited by this paper
• Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats.

  2013influential reference
• Trophic Factor Gene Therapy for Parkinson's Disease

  2013cited by this paper
• A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

  2013cited by this paper
• Intranasal oxytocin blocks alcohol withdrawal in human subjects.

  2013cited by this paper
• Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder.

  2013cited by this paper
• Intranasal Delivery of pGDNF Nanoparticles for Parkinson's Disease

  2013influential reference
• Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats.

  2013influential reference
• Intranasal epidermal growth factor treatment rescues neonatal brain injury

  2013cited by this paper
• Intranasal oxytocin selectively attenuates rhesus monkeys' attention to negative facial expressions.

  2013cited by this paper
• Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 non-transgenic mouse model of Alzheimer’s disease

  2013cited by this paper
• AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.

  2013cited by this paper
• Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

  2013cited by this paper
• The neuroprotective roles of BDNF in hypoxic ischemic brain injury.

  2013cited by this paper
• Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

  2013cited by this paper
• Nasal Administration of Recombinant Osteopontin Attenuates Early Brain Injury After Subarachnoid Hemorrhage

  2013influential reference
• Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

  2012cited by this paper
• Neurodevelopmental effects of insulin-like growth factor signaling.

  2012cited by this paper
• Intranasal drug delivery to the central nervous system: present status and future outlook.

  2012cited by this paper
• Intranasal delivery of insulin via the olfactory nerve pathway

  2012cited by this paper
• Intranasal “painless” Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice

  2012cited by this paper
• Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

  2012cited by this paper
• Multifaces of neuropeptide Y in the brain--neuroprotection, neurogenesis and neuroinflammation.

  2012cited by this paper
• Insulin-like growth factors in the brain and their potential clinical implications

  2012cited by this paper
• A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain.

  2012cited by this paper
• Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.

  2012cited by this paper
• The Neuropeptide Y (NPY)-ergic System is Associated with Behavioral Resilience to Stress Exposure in an Animal Model of Post-Traumatic Stress Disorder

  2012influential reference
• TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry

  2012cited by this paper
• Acute intranasal oxytocin improves positive self-perceptions of personality

  2012cited by this paper
• Intranasal delivery of growth differentiation factor 5 to the central nervous system

  2012influential reference
• Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  2012cited by this paper
• Intranasal administration of nerve growth factor ameliorate β-amyloid deposition after traumatic brain injury in rats.

  2012influential reference
• Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness?

  2012cited by this paper
• Intranasal oxytocin attenuates the cortisol response to physical stress: a dose-response study.

  2012cited by this paper
• Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Intranasal oxytocin increases covert attention to positive social cues

  2012cited by this paper
• Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease.

  2011cited by this paper
• Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.

  2011cited by this paper
• Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial

  2011cited by this paper
• A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

  2011cited by this paper
• Intranasal delivery of therapeutic proteins for neurological diseases

  2011cited by this paper
• Potential therapeutic uses of BDNF in neurological and psychiatric disorders

  2011cited by this paper
• Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia

  2011cited by this paper
• Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

  2011cited by this paper
• Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia

  2011cited by this paper
• Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats.

  2011cited by this paper
• Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.

  2011cited by this paper
• Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.

  2011cited by this paper
• Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.

  2011cited by this paper
• Intranasal erythropoietin therapy in nervous system disorders

  2011cited by this paper
• Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain.

  2011cited by this paper
• Intranasal administration of insulin-like growth factor-1 protects against lipopolysaccharide-induced injury in the developing rat brain.

  2011cited by this paper
• DNA Nanoparticles: Detection of Long-Term Transgene Activity in Brain using Bioluminescence Imaging

  2011cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010influential reference
• Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata.

  2010cited by this paper
• Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.

  2010cited by this paper
• The RGD‐containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra

  2010cited by this paper
• Treatment with Nasal Neuro-EPO Improves the Neurological, Cognitive, and Histological State in a Gerbil Model of Focal Ischemia

  2010cited by this paper
• AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease

  2010cited by this paper
• The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease

  2010cited by this paper
• Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

  2010influential reference
• Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

  2010cited by this paper
• Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.

  2010cited by this paper
• Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

  2010cited by this paper
• Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment

  2010cited by this paper
• Osteopontin regulates human glioma cell invasiveness and tumor growth in mice

  2009cited by this paper
• Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

  2009cited by this paper
• Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats.

  2009cited by this paper
• Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina

  2009cited by this paper
• [Intranasal administration of low dosage recombinant human erythropoietin inhibits seizure in rats].

  2009cited by this paper
• The dose-effectiveness of intranasal VEGF in treatment of experimental stroke.

  2009cited by this paper
• Long-term transgene expression in the central nervous system using DNA nanoparticles.

  2009cited by this paper
• Brain-derived neurotrophic factor, stress and depression: a minireview.

  2009cited by this paper

• Intranasal delivery of engineered extracellular vesicles promotes neurofunctional recovery in traumatic brain injury

  2025cites this paper
• High-fat diet triggers transcriptomic changes in the olfactory bulb

  2025cites this paper
• Engineered nanoparticles for the treatment of Alzheimer’s disease

  2025cites this paper
• Present Insights into the progress in gene therapy delivery systems for central nervous system diseases.

  2024cites this paper
• Engineered EVs designed to target diseases of the CNS

  2023cites this paper
• Delivery of nucleic acids using nanomaterials

  2023cites this paper
• Enhanced Nose-to-Brain Delivery of Combined Small Interfering RNAs Using Lesion-Recognizing Nanoparticles for the Synergistic Therapy of Alzheimer's Disease.

  2023cites this paper
• RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges.

  2023cites this paper
• In-Situ Gels for Brain Delivery: Breaching the Barriers.

  2023cites this paper
• Gene Targeting to the Cerebral Cortex Following Intranasal Administration of Polyplexes

  2022cites this paper
• Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease

  2022cites this paper
• Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy

  2022cites this paper
• Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging

  2022cites this paper
• Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

  2021cites this paper
• Intranasal drug delivery to overcome the blood–brain barrier

  2021cites this paper
• Surface modification of nanocarriers as a strategy to enhance the direct nose-to-brain drug delivery

  2021cites this paper
• Adeno-Associated Viral Vectors as Versatile Tools for Parkinson’s Research, Both for Disease Modeling Purposes and for Therapeutic Uses

  2021cites this paper
• Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems

  2021cites this paper
• Neurotrophic Factors in Parkinson’s Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain

  2021cites this paper
• Revisiting gene delivery to the brain: silencing and editing.

  2020cites this paper
• Insulin mediated novel therapies for the treatment of Alzheimer's disease.

  2020cites this paper
• Parkinson’s disease treatment: past, present, and future

  2020cites this paper
• Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management

  2020cites this paper
• Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia.

  2020cites this paper
• Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB

  2020cites this paper
• Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models

  2020cites this paper
• Cranial Pair I: The Olfactory Nerve

  2019cites this paper
• Micro- and nanotechnology approaches to improve Parkinson's disease therapy.

  2019cites this paper
• Drug delivery to the brain

  2019cites this paper
• Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

  2018cites this paper
• Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease.

  2018cites this paper
• Envisioning the future of polymer therapeutics for brain disorders.

  2018cites this paper
• Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease

  2018cites this paper
• Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression

  2018cites this paper
• 1 Surface-modified nanocarriers for nose-to-brain 2 delivery : from bioadhesion to targeting 3

  2018cites this paper
• Immunotherapies for Movement Disorders: Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  2017cites this paper
• Neurodegenerative signaling factors and mechanisms in Parkinson's pathology.

  2017cites this paper
• Synthetic Peptides Affect the Expression of Gdnf and Gdnf Receptors in Rats with 6-OHDA-Induced PD-Like Parkinsonism

  2016cites this paper
• Development of a small alpha-synuclein-knockdown peptide as a potential therapy for Parkinson’s disease

  2016cites this paper
• Technologies for controlling ultrasound targeted drug delivery in brain using animal models

  2016cites this paper
• Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases

  2016cites this paper
• Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking

  2016cites this paper
• The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy

  2016cites this paper
• Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

  2016cites this paper